Letter from Robert K. Haas to Hubert Creekmore

Haas is vice president of Random House, Inc. and writes on company letterhead from New York City to Creekmore in Jackson, Mississippi, to praise Creekmore\u27s A Little Treasury of World Poetry.https://egrove.olemiss.edu/creekmore/1125/thumbnail.jp

Single-Photon Counting Receivers for Optical Wireless Communications in Future 6G Networks

International audienceOptical wireless communication (OWC) offers several complementary advantages to radio-frequency wireless networks such as its massive available spectrum. Hence, it is widely anticipated that OWC will assume a pivotal role in the forth-coming sixth generation wireless communication networks. Although significant progress has been achieved in OWC over the past decades, the outage induced by occasionally low received optical power continues to pose a key limiting factor for its deployment. In this work, we discuss the potential role of single-photon counting (SPC) receivers as a promising solution to overcome this limitation. We present an overview of the applications of SPC-based OWC systems in 6G networks, introduce their major performance-limiting factors, propose a performance-enhancement frame-work to tackle these issues, and identify critical areas of open problems for future research

Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients

The efficacy and safety of prolonging prophylaxis for venous thromboembolism in medically ill patients beyond hospital discharge remain uncertain. We hypothesized that extended prophylaxis with apixaban would be safe and more effective than short-term prophylaxis with enoxaparin. METHODS: In this double-blind, double-dummy, placebo-controlled trial, we randomly assigned acutely ill patients who had congestive heart failure or respiratory failure or other medical disorders and at least one additional risk factor for venous thromboembolism and who were hospitalized with an expected stay of at least 3 days to receive apixaban, administered orally at a dose of 2.5 mg twice daily for 30 days, or enoxaparin, administered subcutaneously at a dose of 40 mg once daily for 6 to 14 days. The primary efficacy outcome was the 30-day composite of death related to venous thromboembolism, pulmonary embolism, symptomatic deep-vein thrombosis, or asymptomatic proximal-leg deep-vein thrombosis, as detected with the use of systematic bilateral compression ultrasonography on day 30. The primary safety outcome was bleeding. All efficacy and safety outcomes were independently adjudicated. RESULTS: A total of 6528 subjects underwent randomization, 4495 of whom could be evaluated for the primary efficacy outcome - 2211 in the apixaban group and 2284 in the enoxaparin group. Among the patients who could be evaluated, 2.71% in the apixaban group (60 patients) and 3.06% in the enoxaparin group (70 patients) met the criteria for the primary efficacy outcome (relative risk with apixaban, 0.87; 95% confidence interval [CI], 0.62 to 1.23; P = 0.44). By day 30, major bleeding had occurred in 0.47% of the patients in the apixaban group (15 of 3184 patients) and in 0.19% of the patients in the enoxaparin group (6 of 3217 patients) (relative risk, 2.58; 95% CI, 1.02 to 7.24; P = 0.04). CONCLUSIONS: In medically ill patients, an extended course of thromboprophylaxis with apixaban was not superior to a shorter course with enoxaparin. Apixaban was associated with significantly more major bleeding events than was enoxaparinSupported by Bristol-Myers Squibb and Pfize

Testing and Modeling Ethernet Switches and Networks for Use in ATLAS High-level Triggers

The ATLAS second level trigger will use a multi-layered LAN network to transfer 5 Gbyte/s detector data from ~1500 buffers to a few hundred processors. A model of the network has been constructed to evaluate its performance. A key component of the network model is a model of an individual switch, reproducing the behavior measured in real devices. A small number of measurable parameters are used to model a variety of commercial Ethernet switches. Using parameters measured on real devices, the impact on the overall network performance is modeled. In the Atlas context, both 100 Mbit and Gigabit Ethernet links are required. A system is described which is capable of characterizing the behavior of commercial switches with the required number of nodes under traffic conditions resembling those to be encountered in the Atlas experiment. Fast Ethernet traffic is provided by a high density, custom built tester based on FPGAs, programmed in Handel-C and VHDL, while the Gigabit Ethernet traffic is generated using Alteon NICs with custom firmware. The system is currently being deployed with 32 100Mbit ports and 16 Gigabit ports, and will be expanded to ~256 nodes of 100 Mbit and ~50 GBE nodes

An Assessment of State-of-the-Art Mean Sea Surface and Geoid Models of the Arctic Ocean: Implications for Sea Ice Freeboard Retrieval

State-of-the-art Arctic Ocean mean sea surface (MSS) models and global geoid models (GGMs) are used to support sea ice freeboard estimation from satellite altimeters, as well as in oceanographic studies such as mapping sea level anomalies and mean dynamic ocean topography. However, errors in a given model in the high frequency domain, primarily due to unresolved gravity features, can result in errors in the estimated along-track freeboard. These errors are exacerbated in areas with a sparse lead distribution in consolidated ice pack conditions. Additionally model errors can impact ocean geostrophic currents, derived from satellite altimeter data, while remaining biases in these models may impact longer-term, multi-sensor oceanographic time-series of sea level change in the Arctic. This study focuses on an assessment of five state-of-the-art Arctic MSS models (UCL13/04, DTU15/13/10) and a commonly used GGM (EGM2008). We describe errors due to unresolved gravity features, inter-satellite biases, and remaining satellite orbit errors, and their impact on the derivation of sea ice freeboard. The latest MSS models, incorporating CryoSat-2 sea surface height measurements, show improved definition of gravity features, such as the Gakkel Ridge. The standard deviation between models ranges 0.03-0.25 m. The impact of remaining MSS/GGM errors on freeboard retrieval can reach several decimeters in parts of the Arctic. While the maximum observed freeboard difference found in the central Arctic was 0.59 m (UCL13 MSS minus EGM2008 GGM), the standard deviation in freeboard differences is 0.03-0.06 m

Status of U.S. testing of the High Performance Hall System SPT-140 Hall thruster

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/77315/1/AIAA-2000-1053-280.pd

Prescription and Other Medication Use in Pregnancy

OBJECTIVE: To characterize prescription and other medication use in a geographically and ethnically diverse cohort of women in their first pregnancy. METHODS: In a prospective, longitudinal cohort study of nulliparous women followed through pregnancy from the first trimester, medication use was chronicled longitudinally throughout pregnancy. Structured questions and aids were used to capture all medications taken as well as reasons they were taken. Total counts of all medications taken including number in each category and class were captured. Additionally, reasons the medications were taken were recorded. Trends in medications taken across pregnancy and in the first trimester were determined. RESULTS: Of the 9,546 study participants, 9,272 (97.1%) women took at least one medication during pregnancy with 9,139 (95.7%) taking a medication in the first trimester. Polypharmacy, defined as taking at least five medications, occurred in 2,915 (30.5%) women. Excluding vitamins, supplements, and vaccines, 73.4% of women took a medication during pregnancy with 55.1% taking one in the first trimester. The categories of drugs taken in pregnancy and in the first trimester include the following: gastrointestinal or antiemetic agents (34.3%, 19.5%), antibiotics (25.5%, 12.6%), and analgesics (23.7%, 15.6%, which includes 3.6%; 1.4% taking an opioid pain medication). CONCLUSION: In this geographically and ethnically diverse cohort of nulliparous pregnant women, medication use was nearly universal and polypharmacy was common

T Cell Activation Markers and African Mitochondrial DNA Haplogroups among Non-Hispanic Black Participants in AIDS Clinical Trials Group Study 384

Introduction: Mitochondrial function influences T cell dynamics and is affected by mitochondrial DNA (mtDNA) variation. We previously reported an association between African mtDNA haplogroup L2 and less robust CD4 cell recovery on antiretroviral therapy (ART) in non-Hispanic black ACTG 384 subjects. We explored whether additional T cell parameters in this cohort differed by mtDNA haplogroup. Methods: ACTG 384 randomized ART-naïve subjects to two different nucleoside regimens with efavirenz, nelfinavir, or both. CD4 and CD8 memory and activation markers were available at baseline and week 48 on most subjects. mtDNA sequencing was performed on whole blood DNA, and haplogroups were determined. We studied non-Hispanic black subjects with HIV RNA <400 copies/mL at week 48. Analyses included Wilcoxon ranksum test and linear regression. Results: Data from 104 subjects were included. Major African mtDNA haplogroups included L1 (N = 25), L2 (N = 31), and L3 (N = 32). Baseline age, HIV RNA, and CD4 cells did not differ between L2 and non-L2 haplogroups. Compared to non-L2 haplogroups, L2 subjects had lower baseline activated CD4 cells (median 12% vs. 17%; p = 0.03) and tended toward lower activated CD8 cells (41% vs. 47%; p = 0.06). At 48 weeks of ART, L2 subjects had smaller decreases in activated CD4 cells (−4% vs. −11%; p = 0.01), and smaller CD4 cell increases (+95 vs. +178; p = 0.002). In models adjusting for baseline age, CD4 cells, HIV RNA, and naïve-to-memory CD4 cell ratio, haplogroup L2 was associated with lower baseline (p = 0.04) and 48-week change in (p = 0.01) activated CD4 cells. Conclusions: Among ART-naïve non-Hispanic blacks, mtDNA haplogroup L2 was associated with baseline and 48-week change in T cell activation, and poorer CD4 cell recovery. These data suggest mtDNA variation may influence CD4 T cell dynamics by modulating T cell activation. Further study is needed to replicate these associations and identify mechanisms